BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Newcastle Hospitals Clinical Skills Academy - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://skillsacademy.newcastle-hospitals.nhs.uk
X-WR-CALDESC:Events for Newcastle Hospitals Clinical Skills Academy
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260519T133000
DTEND;TZID=Europe/London:20260609T163000
DTSTAMP:20260404T231355
CREATED:20250922T162414Z
LAST-MODIFIED:20251113T155446Z
UID:10000131-1779197400-1781022600@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Targeted treatments and immunotherapy for Haematological Cancers - May 2026
DESCRIPTION:Delivered over one afternoon session\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through many of the most relevant topics relating to modern systemic treatments for haematological cancers. \nSession 1: The first session will focus on how haematological cancers develop and the faulty cells that cause them. Elaine will also describe the unique features of B cells and explain why they give rise to over 80% of haematological cancers diagnosed in the UK. Elaine also explains the mechanisms of action of various treatments given to people with B cell cancers: chronic lymphocytic leukaemia\, acute lymphoblastic leukaemia\, and non-Hodgkin lymphoma. \nSession 2: In the second session\, Elaine explores treatments for multiple myeloma\, acute myeloid leukaemia\, Hodgkin lymphoma\, and chronic myeloid leukaemia. She also explains the science behind CAR T cell therapy and describes the progress made to date and innovations for the future. \nAudience\nDr Vickers’ goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others. \nThis half day course is ideal for research nurses\, clinical nurse specialists\, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with haematological cancers\, and to junior doctors. \nACCEND\nNHS England’s ACCEND Programme aims to support the development of a skilled and knowledgeable cancer workforce. \nThis course supports Component 3 of the ACCEND pathway\, the Education Framework. \nSpecifically\, this course’s objectives and learning outcomes meet core cancer knowledge needs at both the ‘Foundation of Cancer Care’ and ‘Fundamentals of Cancer Care’ levels. \nThe course will enhance learners’ understanding of cancer biology\, the mechanism of action of systemic cancer treatments\, and the use of biomarkers to select the best treatments for each patient. \nThe knowledge gained through this course will empower staff to feel confident when communicating with patients and their families\, and with clinical and non-clinical colleagues. \nDetailed description\nSession 1\nPresentation 1 – Biology and genetics of haematological cancers \n\nCell of origin of different haematological cancers\nTypes of DNA damage in haematological cancers\nConsequences of common chromosome translocations and other mutations\nUnderstanding the incidence of blood cancers in infants and children\n\nPresentation 2 – Features of B cell cancers & an overview of treatment approaches \n\nWhy most haematological cancers are derived from B cells\nImportant features of B cell cancers\, e.g. indolent vs. aggressive\, the effect of TP53 mutations\, the importance of B cell receptor signalling\nAntibody-based treatments: naked antibodies\, conjugated antibodies\, BiTEs & bi-specifics\nSmall molecules with kinase and non-kinase targets\nCell-based therapies\n\nPresentation 3 – Treatments for B cell cancers: chronic lymphocytic leukaemia\, non-Hodgkin lymphoma and acute lymphoblastic leukaemia \n\nCD20-targeted antibody therapies (e.g. rituximab\, obinutuzumab)\nB cell receptor signalling pathway inhibitors targeting BTK\, PI3Kδ & CD79B (e.g. ibrutinib\, acalabrutinib\, idelalisib\, polatuzumab vedotin)\nBcl-2 inhibitors (e.g. venetoclax)\nBi-specific antibodies that act as T cell engagers (e.g. blinatumomab\, glofitamab\, mosunetuzumab\, epcoritamab\, odronextamab)\n\nSession 2\nPresentation 4 – Treatments for myeloma \n\nProteasome inhibitors (e.g. bortezomib)\nImmunomodulators (e.g. thalidomide\, pomalidomide) and novel cereblon modulators (e.g. iberdomide\, mezigdomide)\nMonoclonal antibodies targeting CD38 (e.g. daratumumab\, isatuximab)\nT cell engagers targeting BCMA and GPRC5D (e.g. talquetemab\, teclistamab\, elranatamab)\nAntibody-drug conjugates (e.g. balantamab mafodotin)\n\nPresentation 5 – Treatments for acute myeloid leukaemia\, Hodgkin lymphoma\, and chronic myeloid leukaemia \n\nTreatments for acute myeloid leukaemia: an overview of targets and focus on FLT3 inhibitors\nBcr-Abl inhibitors for chronic myeloid leukaemia (e.g. imatinib\, dasatinib\, nilotinib\, ponatinib\, asciminib)\nImmune checkpoint inhibitors for Hodgkin lymphoma (e.g. pembrolizumab\, nivolumab)\n\nPresentation 6 –  CAR T cell therapy for haematological cancers \n\nOverview of the CAR T cell process\nCAR protein design – what each bit does and why it matters\nCAR protein targets\nReasons for side effects of CAR T cells\nReasons for resistance and relapse\nOverview of the results so far\, the lessons learned\, and what the future might look like\n\nPre-course preparation\nElaine has created two YouTube playlists about cancer biology and cancer treatments to help learners get the most out of her courses. Each playlist contains 10 videos between 3 and 8 minutes long. \nElaine advises “If you’re short on time and you’re not sure about the relationship between DNA\, genes and proteins\, I would suggest watching the Cells\, DNA\, genes and chromosomes and From genes to proteins videos from the Cancer Basics playlist as a priority. Also\, if you’re new to cancer\, I’d recommend the Mutations cause cancer video and\, in order to understand how cancer cells interact with the cells around them\, watch the Tumours are complicated places video.” \n“In the Cancer Treatments playlist\, there are videos about all the various treatments I’ll be mentioning. The two I’d prioritise explain why we use small chemical compounds (small molecules) and antibodies as cancer treatments. If you have more time\, do also watch the videos on kinase inhibitors and immune checkpoint inhibitors.” \nAbout Elaine Vickers\nDr Elaine Vickers\nElaine Vickers of Science Communicated Ltd has a PhD in Molecular Biology. She has worked as a cancer educator for over twenty years. \nShe is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies\, and immunotherapies. \nElaine is experienced in teaching people with any level of scientific or medical knowledge. She particularly loves teaching nurses and other health professionals who might feel daunted by the idea of learning about cancer science. \nHer book\, A Beginner’s Guide to Targeted Cancer Treatments and Cancer Immunotherapy\, is now in its second edition. The first edition was Highly Commended by the British Medical Association book awards. \nElaine also makes short educational videos on cancer biology and treatments\, which you can find on her YouTube channel: https://www.youtube.com/@DrElaineVickers \nFinancial information\nIf you are employed by Newcastle Hospitals NHS Foundation Trust\, you can use the coupon code NUTH at the checkout to make a provisional booking and you will need to arrange access to in-house development funding. Your booking will remain provisional until your request has been validated with a funding/study leave reference. \nIf you are not employed by the Newcastle Hospitals an online card payment is required at the point of booking. Alternatively\, if you are to be funded by your employer an invoice can be requested by using the coupon code Invoice. \nIf you are a LET employee you will need to pay by card as we are unable to invoice LETs. \nPlease see Coupons for further information relating to coupon codes and how to use them at checkout. \nCancellation and refunds policy\nShould you no longer be able to attend the event on the booked date\, please contact the Academy as we may be able to offer an alternative date subject to an admin charge. \nShould you still wish to cancel your booking\, you or your employer will be charged as per the fees outlined below.  Please contact nuth.newcastlehospitalsskillsacademy@nhs.net to cancel your booking. \n\n\n\nTimescale\nFee paying course\n\n\nOver 6 weeks\n£25 admin charge\n\n\n2 to 6 weeks\n50% of course fee\n\n\n0 to 2 weeks\n100% of course fee\n\n\n\nIf you do not attend on the day\, you will be charged the full cost of the event place. \nSee our Terms & Conditions and Cancellations & Refunds pages for more details.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/targeted-treatments-and-immunotherapy-for-haematological-cancers/
LOCATION:Virtual delivery via MS Teams
CATEGORIES:Cancer courses
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2024/09/Haematology-banner-scaled.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
END:VCALENDAR